IGHV基因使用片段在伴有骨髓浸润的晚期滤泡性淋巴瘤患者中的预后价值
永乐 李, 睿泽 陈, 楠 陈, 彤璐 邱, 泓妤 沈, 晖 金, 纯 乔, 华渊 朱, 磊 范, 卫 徐, 建勇 李, 文瑜 施, 祎 缪, 奕 夏 · 2026
Read IGHV基因使用片段在伴有骨髓浸润的晚期滤泡性淋巴瘤患者中的预后价值 by 永乐 李, 睿泽 陈, 楠 陈, 彤璐 邱, 泓妤 沈, 晖 金, 纯 乔, 华渊 朱, 磊 范, 卫 徐, 建勇 李, 文瑜 施, 祎 缪, 奕 夏 (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13575539.txt.
Description
Yongle Li and colleagues looked back at 33 patients with follicular lymphoma and bone marrow involvement treated at Jiangsu Province Hospital between August 2017 and November 2024. They mapped which antibody gene segments the lymphoma cells used, focusing on the heavy-chain variable region known as IGHV. Most patients carried mutated IGHV genes, and one gene family, IGHV3, dominated the group.
One segment, IGHV3-48, appeared in about a quarter of the patients and far more often than in several other B-cell lymphomas. Patients carrying it more often had high lactate dehydrogenase levels and high prognostic scores, with a trend toward disease progression within twelve months. The segment may therefore help doctors spot high-risk cases early, though the small group size calls for confirmation in larger studies.
Catalog record
| CREATOR | 永乐 李, 睿泽 陈, 楠 陈, 彤璐 邱, 泓妤 沈, 晖 金, 纯 乔, 华渊 朱, 磊 范, 卫 徐, 建勇 李, 文瑜 施, 祎 缪, 奕 夏 |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |